Press release - 18/09/2024 Future cluster QSens starts the second round of funding In the “Cluster4Future” QSens of the Universities of Stuttgart and Ulm, scientists, companies and start-ups are researching quantum sensors with a wide range of potential applications. The Federal Ministry of Education and Research is funding QSens for a further three years as part of “Clusters4Future”.https://www.gesundheitsindustrie-bw.de/en/article/press-release/future-cluster-qsens-starts-second-round-funding
Press release - 23/05/2024 "They heal wounds, allow bones to grow and calm inflammation" MWK funds cell therapy research into mesenchymal stromal cells with 600,000 euros The Baden-Württemberg Ministry of Science, Research and Arts (MWK) is supporting medical researchers at Ulm University with start-up funding totalling 600,000 euros. The aim is to establish an EU consortium for the broad therapeutic use of mesenchymal stromal cells. The funding is being awarded as part of the "BEGIN - Participation in major European projects and initiatives" programme.https://www.gesundheitsindustrie-bw.de/en/article/press-release/they-heal-wounds-allow-bones-grow-and-calm-inflammation-mwk-funds-cell-therapy-research-mesenchymal-stromal-cells-600000-euros
Press release - 11/04/2024 How the body switches out of “fight” mode Study in Nature unlocks how cortisone inhibits inflammation Cortisone and other related glucocorticoids are extremely effective at curbing excessive immune reactions. But previously, astonishingly little was known about how they exactly do that. A team of researchers from Charité – Universitätsmedizin Berlin, Uniklinikum Erlangen and Ulm University have now explored the molecular mechanism of action in greater detail. https://www.gesundheitsindustrie-bw.de/en/article/press-release/wie-der-kampfmodus-im-koerper-beendet-wird-studie-nature-entschluesselt-wie-kortison-entzuendungen-daempft
Stem cell research - 14/03/2024 Using organoids to gain a better clinical understanding of pancreatic cancer Prof. Dr. Alexander Kleger carries out translational research at Ulm University Hospital to gain a better understanding of pancreatic ductal adenocarcinoma (PDAC) and develop individualised treatments. He and his team are using organoid models and stem cell-based systems and have succeeded in simultaneously cultivating all three main cell types of the pancreas from pluripotent stem cells.https://www.gesundheitsindustrie-bw.de/en/article/news/using-organoids-gain-better-clinical-understanding-pancreatic-cancer
Press release - 02/02/2024 University of Stuttgart successful with cluster draft proposals The German Research Foundation (DFG) has announced the first pivotal decisions for the "Clusters of Excellence" funding line as part of the Excellence Strategy of the German federal and state governments. The University of Stuttgart has been given the green light for two new cluster initiatives. https://www.gesundheitsindustrie-bw.de/en/article/press-release/universitaet-stuttgart-mit-clusterskizzen-erfolgreich
Press release - 20/07/2023 Animal testing under REACH: bringing numbers into the debate So far, 4.2 million animal tests under the REACH chemical regulation: A study from Konstanz and Baltimore quantifies the number of animals that died for the hazard assessment of chemicals in the chemical industry.https://www.gesundheitsindustrie-bw.de/en/article/press-release/tierversuche-durch-reach-zahlen-die-debatte-bringen
Press release - 25/11/2022 Praise for Ulm's trauma research from DFG CRC 1149 reaches 3rd funding phase What a success for Ulm University and its medical centre! The German Research Foundation (Deutsche Forschungsgemeinschaft; DFG) extends the Collaborative Research Centre (CRC) on Trauma Medicine for the second time. The third funding phase infuses the CRC 1149 'Danger Response, Disturbance Factors and Regenerative Potential after Acute Trauma' with 11.1 million euros. https://www.gesundheitsindustrie-bw.de/en/article/press-release/praise-ulms-trauma-research-dfg-crc-1149-reaches-3rd-funding-phase
Bakteriocins - 24/05/2022 New antibiotic alternatives from soil bacteria Bacteria are not the greatest of friends among themselves: many release antimicrobial substances into their environment in order to gain an advantage in their ecological niche. Researchers at the University of Ulm are making use of such bacteriocins by creating a genetically modified soil bacterium that can be used as a biotechnological platform organism to produce alternatives to antibiotics in pure form and in large quantities. The fact this…https://www.gesundheitsindustrie-bw.de/en/article/news/new-antibiotic-alternatives-soil-bacteria
Press release - 12/05/2022 New hope for broad spectrum viral entry inhibitors – Negatively charged polymer proves effective against a wide range of viruses While broad-spectrum antibiotics can offer protection against a wide variety of bacteria, there are currently no analogous clinically available broad-spectrum antiviral agents that can act on several different viruses. An international research team has now shown that polystyrene sulfonate (PSS), a negatively charged polymer, has the potential to be used in the prevention of viral infections – not only in the fight against the SARS-CoV-2 and cold…https://www.gesundheitsindustrie-bw.de/en/article/press-release/new-hope-broad-spectrum-viral-entry-inhibitors-negatively-charged-polymer-proves-effective-against-wide-range-viruses
COVIC-19 clinical trial - 07/04/2022 Convalescent plasma for COVID-19 therapy: clinical trial should bring clarity Does it help to treat COVID-19 sufferers with antibodies from people who have recovered from the disease? It seems an obvious idea and has been tested thousands of times. However, there is not yet enough evidence to prove the clinical efficacy of treating COVID-19 patients with convalescent plasma. The transfusion physician Prof. Dr. Hubert Schrezenmeier from Ulm is planning to carry out a follow-up clinical trial to find the missing evidence.https://www.gesundheitsindustrie-bw.de/en/article/news/convalescent-plasma-covid-19-therapy-clinical-trial-should-bring-clarity
Press release - 25/11/2021 New Collaborative Research Centre at Ulm University Focusing on the factors that influence human aging After a highly competitive process Ulm University has been awarded its fifth Collaborative Research Centre (CRC). The new CRC 1506 ‘Aging at Interfaces’ addresses one of the most urgent medical challenges of our time: the aging of the human body and the diseases and constraints that are frequently associated with the aging process.https://www.gesundheitsindustrie-bw.de/en/article/press-release/new-collaborative-research-centre-ulm-university-focusing-factors-influence-human-aging
Optimised peptides against infections and cancer - 07/10/2021 New bioactive ingredients from the peptidome treasure chest Peptides are increasingly coming into scientific focus for application in diagnostics and therapy. The human body is full of these protein fragments, but only a fraction have been characterised. So there is enormous potential for discovering new biologically active substances that can help in the fight against bacteria, viruses and cancer. A collaborative research centre at Ulm University Hospital is on the trail of these promising fragments.https://www.gesundheitsindustrie-bw.de/en/article/news/new-bioactive-ingredients-peptidome-treasure-chest
Quantum Technology Ulm - 08/04/2021 Diamonds for life sciences innovations The world's first commercial quantum computer,’IBM Q System One’, is now in operation in Ehningen near Stuttgart. This is a major leap forward in quantum technology in Germany. It marks the point at which conventional computers reach their limits. The University of Ulm is involved in three of six collaborative projects being funded by the Baden-Württemberg Ministry of Economic Affairs, Labour and Housing Construction.https://www.gesundheitsindustrie-bw.de/en/article/news/diamonds-life-sciences-innovations
Stem cell therapy for regenerating intervertebral discs - 16/07/2020 Ulm’s simulator has Europe’s back Back pain is often caused by intervertebral disc disorders. Much has already been tried and is available to help patients. Despite extensive progress, there is still no surefire recipe for success. iPSpine, an EU-funded project to which researchers from Ulm are contributing interdisciplinary engineering and biomedical expertise, aims to design a novel therapy for back pain based on intervertebral disc regeneration.https://www.gesundheitsindustrie-bw.de/en/article/news/Ulms-simulator-has-europes-back
Article - 18/11/2019 Researchers successfully rejuvenate the immune system in animal models It is well known that stem cells age. Even the human immune system loses its power with age. Since all immune cells are derived from blood-forming stem cells, it is quite natural to associate the weakening of the immune system (immune senescence) with the ageing of blood-forming stem cells. Stem cell researchers and immunologists from the University of Ulm have now demonstrated the important role that blood-forming cells play in the ageing of the…https://www.gesundheitsindustrie-bw.de/en/article/news/Researchers-successfully-rejuvenate-the-immune-system-in-animal-models
Dossier - 17/01/2017 Phytopharmaceuticals – fighting disease with natural substances Phytopharmaceuticals are herbal medicines whose efficacy is down to one or several plant substances or active ingredients. They have been used for treating diseases since time immemorial. This traditional knowledge is still the basis for many medicinal products made from plants or parts thereof. Herbal medicines have been produced in Baden-Württemberg for many generations.https://www.gesundheitsindustrie-bw.de/en/article/dossier/phytopharmaceuticals-fighting-disease-with-natural-substances